Repligen (NASDAQ:RGEN) Announces Quarterly Earnings Results
Repligen (NASDAQ:RGEN) released its quarterly earnings data on Thursday. The biotechnology company reported $0.42 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.28 by $0.14, MarketWatch Earnings reports. The firm had revenue of $87.46 million during the quarter, compared to analysts’ expectations of $78.11 million. Repligen had a return on equity of 5.99% and a net margin of 10.23%. Repligen updated its FY 2020
Pre-Market guidance to 1.24-1.29 EPS and its FY20 guidance to $1.24-1.29 EPS.
Repligen stock traded down $0.34 during midday trading on Friday, reaching $150.91. 1,054,320 shares of the company were exchanged, compared to its average volume of 410,098. The company has a market capitalization of $7.89 billion, a price-to-earnings ratio of 260.19, a P/E/G ratio of 5.42 and a beta of 1.06. The firm’s 50-day simple moving average is $125.27 and its 200-day simple moving average is $111.55. Repligen has a 1 year low of $72.32 and a 1 year high of $155.27. The company has a debt-to-equity ratio of 0.25, a quick ratio of 14.09 and a current ratio of 15.56.
Several research firms have issued reports on RGEN. Stifel Nicolaus increased their price objective on Repligen from $135.00 to $150.00 and gave the stock a “buy” rating in a research report on Wednesday, May 27th. Craig Hallum raised their price target on Repligen from $120.00 to $145.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. ValuEngine cut Repligen from a “buy” rating to a “hold” rating in a research report on Friday, May 1st. HC Wainwright restated a “buy” rating and issued a $151.00 price target (up previously from $143.00) on shares of Repligen in a research report on Tuesday, June 30th. Finally, BidaskClub upgraded Repligen from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 25th. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $136.67.
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.
See Also: Coverage Ratio
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.